Article thumbnail
Location of Repository

Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats

By Paola Failli, Chiara Alfarano, Sergio Franchi-Micheli, Edoardo Mannucci, Elisabetta Cerbai, Alessandro Mugelli and Laura Raimondi
Topics: Original Investigation
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2711933
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signa l
  2. (1999). Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens
  3. (2008). Applications for ROCK kinase inhibition.
  4. (2007). BM: Renin-angiotensin system and cardiovascular risk. The Lancet
  5. (2005). Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice.
  6. (2004). Cerbai E: Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes
  7. (2007). Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci
  8. (1989). Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells.
  9. (1993). Effects of isoquinoline derivatives, HA1077 and H-7, on cytosolic Ca2+ level and contraction in vascular smooth muscle.
  10. (1999). Enhanced, unaltered and impaired nitric oxidemediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia
  11. (2003). Failli P: The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells.
  12. (2006). Gong MC: Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc Res
  13. (2002). Hartshorne DJ: Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase.
  14. (1989). HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science
  15. (2000). Inagami T: Involvement of Rho-kinase in angiotensin IIinduced hypertrophy of rat vascular smooth muscle cells. Hypertension
  16. (1999). JH: Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res
  17. (2004). JH: RHO SIGNALING in Vascular Diseases. Mol Interv
  18. (1996). Kaibuchi K: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science
  19. (2008). Krepinsky JC: RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes
  20. (2004). Lorenzo TP: Individual non-obese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase.
  21. (2000). Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips.
  22. (1997). Narumiya S: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature
  23. Nisato D: Pharmacological characterization of SR 4 a new nonpeptide AT1 subtype angiotensin II receptor antagonist.
  24. (2005). Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers.
  25. (2006). Pacaud P: Rho kinases in cardiovascular physiology and pathophysiology. Circ Res
  26. (2006). RC: Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domaincontaining RhoGEF, in vascular smooth muscle cells. Mol Pharmacol
  27. (2005). Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal
  28. (2000). Regulation and functions of Rhoassociated kinase. Exp Cell Res
  29. (2003). Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries.
  30. (2005). RM: The renin-angiotensinaldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab
  31. (2007). S: Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond)
  32. (2005). Saruta T: Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension
  33. (1997). Somlyo AV, Somlyo AP: Translocation of rhoA associated with Ca2+ sensitization of smooth muscle.
  34. (2003). Somlyo AV: Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev
  35. (2000). Somlyo AV: Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and nonmuscle myosin II.
  36. (2004). T: RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res
  37. (2005). Tamaki T: ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res
  38. (1990). Weishaar RE: Subclasses of angiotensin II binding sites and their functional significance. Mol Pharmacol
  39. (2006). Z h a o X , I m i g

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.